| Binimetinib studied in …STUDIED_INderived100 of 100show fewer |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 100 trials list this drug (31 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 100 trials list this drug (31 active) | — | — | Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04322383Phase 2 · recruiting Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant · 100 trials list this drug (31 active) | — | — | Hairy Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04511013Phase 2 · recruiting A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases · 100 trials list this drug (31 active) | — | — | Melanoma,Cutaneous Melanoma,Mucosal Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04657991Phase 3 · active not recruiting A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05355701Phase 1 · active not recruiting A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. · 100 trials list this drug (31 active) | — | — | Melanoma,Glioma,Lung Non-Small Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554367Phase 2 · active not recruiting Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial · 100 trials list this drug (31 active) | — | — | Malignant Solid Neoplasm,Malignant Pancreatic Neoplasm,Malignant Ovarian Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04598009Phase 2 · recruiting Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04526782Phase 2 · active not recruiting ENCOrafenib With Binimetinib in bRAF NSCLC · 100 trials list this drug (31 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05111561Phase 1 · recruiting Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer · 100 trials list this drug (31 active) | — | — | Malignant Solid Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04221438Phase 2 · terminated Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement · 100 trials list this drug (31 active) | — | — | Cutaneous Melanoma,Melanoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564403Phase 2 · active not recruiting Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) · 100 trials list this drug (31 active) | — | — | Biliary Tract Carcinoma,Intrahepatic Cholangiocarcinoma,Malignant Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03693170Phase 2 · completed Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer · 100 trials list this drug (31 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03991819Phase 1 · active not recruiting Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer · 100 trials list this drug (31 active) | — | — | Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04324112Phase 2 · active not recruiting Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL · 100 trials list this drug (31 active) | — | — | Hairy Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02910700Phase 2 · active not recruiting Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma · 100 trials list this drug (31 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03839342Phase 2 · active not recruiting Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations · 100 trials list this drug (31 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03947385Phase 1/Phase 2 · recruiting Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions · 100 trials list this drug (31 active) | — | — | Cutaneous Melanoma,Uveal Melanoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04074096Phase 2 · active not recruiting Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis · 100 trials list this drug (31 active) | — | — | Melanoma,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04800822Phase 1 · terminated PF-07284892 in Participants With Advanced Solid Tumors · 100 trials list this drug (31 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05615818Phase 3 · recruiting Personalized Medicine for Advanced Biliary Cancer Patients · 100 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439344Phase 2 · active not recruiting Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) · 100 trials list this drug (31 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05195632Phase 2 · active not recruiting Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer · 100 trials list this drug (31 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03971409Phase 2 · active not recruiting Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer · 100 trials list this drug (31 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma,Invasive Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05026983Phase 2 · recruiting Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04061980Phase 2 · active not recruiting Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer · 100 trials list this drug (31 active) | — | — | Differentiated Thyroid Gland Carcinoma,Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04892017Phase 1 · terminated Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors · 100 trials list this drug (31 active) | — | — | Solid Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05286788Phase 2 · recruiting MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma · 100 trials list this drug (31 active) | — | — | Adamantinomatous Craniopharyngioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04132505Phase 1 · completed Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer · 100 trials list this drug (31 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05170334Phase 2 · active not recruiting Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma · 100 trials list this drug (31 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03915951Phase 2 · completed An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer · 100 trials list this drug (31 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05926960Phase 2 · terminated A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554354Phase 2 · terminated Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) · 100 trials list this drug (31 active) | — | — | HER2-Negative Breast Carcinoma,Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01909453Phase 3 · completed Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04903119Phase 1 · recruiting Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03170206Phase 1 · completed Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer · 100 trials list this drug (31 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03543969early Phase 1 · active not recruiting Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma · 100 trials list this drug (31 active) | — | — | Malignant Skin Neoplasm,Melanoma,Cutaneous Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04585815Phase 1/Phase 2 · terminated Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) · 100 trials list this drug (31 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01991379Phase 1/Phase 2 · active not recruiting MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) · 100 trials list this drug (31 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04543188Phase 1 · terminated A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement · 100 trials list this drug (31 active) | — | — | Malignant Neoplasm,Melanoma,Brain Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02285439Phase 1/Phase 2 · completed Study of MEK162 for Children With Low-Grade Gliomas · 100 trials list this drug (31 active) | — | — | Malignant Neoplasm,Soft Tissue Neoplasm,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05510895Phase 2 · completed Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer · 100 trials list this drug (31 active) | — | — | Malignant Neoplasm,Malignant Colorectal Neoplasm,Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02185690Phase 1 · completed A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung · 100 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05304546Phase 2 · completed Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03106415Phase 1/Phase 2 · completed Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer · 100 trials list this drug (31 active) | — | — | Malignant Breast Neoplasm,Breast Adenocarcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03898908Phase 2 · completed Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain · 100 trials list this drug (31 active) | — | — | Melanoma,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03231306Phase 2 · completed Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas · 100 trials list this drug (31 active) | — | — | Plexiform Neurofibroma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04720976Phase 1/Phase 2 · completed JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors · 100 trials list this drug (31 active) | — | — | Solid Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05260684completed Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04375527Phase 2 · terminated Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma · 100 trials list this drug (31 active) | — | — | Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03374254Phase 1 · completed Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) · 100 trials list this drug (31 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03973918Phase 2 · terminated Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG · 100 trials list this drug (31 active) | — | — | Anaplastic Astrocytoma,Anaplastic Pleomorphic Xanthoastrocytoma,Glioblastoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03843775Phase 1/Phase 2 · completed A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers · 100 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03864042Phase 1 · completed Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors · 100 trials list this drug (31 active) | — | — | Solid Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03475004Phase 2 · completed Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer · 100 trials list this drug (31 active) | — | — | Malignant Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05810740Phase 1 · completed Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03981614Phase 2 · completed Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer · 100 trials list this drug (31 active) | — | — | Carcinoma,Colorectal Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02631447Phase 2 · completed Sequential Combo Immuno and Target Therapy (SECOMBIT) Study · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04655157Phase 1/Phase 2 · terminated Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04390243Phase 2 · terminated Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation · 100 trials list this drug (31 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01543698Phase 1/Phase 2 · completed A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors · 100 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02159066Phase 2 · completed LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01320085Phase 2 · completed A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma · 100 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04720768Phase 1/Phase 2 · unknown Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04870034early Phase 1 · withdrawn Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer · 100 trials list this drug (31 active) | — | — | Malignant Solid Neoplasm,Pancreatic Carcinoma,Colorectal Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02928224Phase 3 · completed Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer · 100 trials list this drug (31 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06159478Phase 2 · recruiting Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) · 100 trials list this drug (31 active) | — | — | Malignant Pancreatic Neoplasm,Low Grade Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02834364Phase 2 · completed BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) · 100 trials list this drug (31 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03563729Phase 2 · recruiting Melanoma Metastasized to the Brain and Steroids · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03911869Phase 2 · terminated An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis · 100 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04801966NA · terminated Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study · 100 trials list this drug (31 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878719Phase 1 · terminated Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01859026Phase 1 · completed A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation · 100 trials list this drug (31 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04044430Phase 1 · terminated Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer · 100 trials list this drug (31 active) | — | — | Colorectal Adenocarcinoma,Malignant Colorectal Neoplasm,Colon Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04005144Phase 1 · terminated Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer · 100 trials list this drug (31 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03637491Phase 1/Phase 2 · terminated A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors · 100 trials list this drug (31 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05080621Phase 1/Phase 2 · withdrawn Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) · 100 trials list this drug (31 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03271047Phase 2 · completed Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation · 100 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05103891Phase 1 · unknown Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02964689Phase 1 · completed Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. · 100 trials list this drug (31 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02510001Phase 1 · completed MEK and MET Inhibition in Colorectal Cancer · 100 trials list this drug (31 active) | — | — | Solid Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03158103Phase 1 · completed A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) · 100 trials list this drug (31 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02089230Phase 1/Phase 2 · terminated MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy · 100 trials list this drug (31 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01763164Phase 3 · completed Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma · 100 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04292119Phase 1/Phase 2 · unknown Lorlatinib Combinations in Lung Cancer · 100 trials list this drug (31 active) | — | — | Malignant Neoplasm,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01885195Phase 2 · completed MEK162 for Patients With RAS/RAF/MEK Activated Tumors · 100 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01927341Phase 1/Phase 2 · completed Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors · 100 trials list this drug (31 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02902042Phase 1/Phase 2 · completed Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04045691recruiting Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02276027Phase 2 · completed A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer · 100 trials list this drug (31 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01562899Phase 1/Phase 2 · terminated A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors · 100 trials list this drug (31 active) | — | — | Melanoma with BRAF Mutation,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01781572Phase 1/Phase 2 · completed A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma · 100 trials list this drug (31 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01828034Phase 1/Phase 2 · completed First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma · 100 trials list this drug (31 active) | — | — | Biliary Tract Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01469130Phase 1 · completed A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors · 100 trials list this drug (31 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01801358Phase 1/Phase 2 · terminated A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma · 100 trials list this drug (31 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02263898Phase 2 · withdrawn Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations · 100 trials list this drug (31 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02451865Phase 1 · withdrawn Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer · 100 trials list this drug (31 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02225574Phase 1 · terminated An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) · 100 trials list this drug (31 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02105350Phase 1 · withdrawn A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer · 100 trials list this drug (31 active) | — | — | Biliary Tract Carcinoma,Gallbladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01449058Phase 1 · completed A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors · 100 trials list this drug (31 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |